Search

Your search keyword '"Liakos, A."' showing total 106 results
Start Over Author "Liakos, A." Publisher wiley
106 results on '"Liakos, A."'

1. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta‐analysis

Author

Malandris, Konstantinos, primary, Papandreou, Stylianos, additional, Vasilakou, Despoina, additional, Kakotrichi, Panagiota, additional, Sarakapina, Anna, additional, Kalopitas, Georgios, additional, Karagiannis, Thomas, additional, Giouleme, Olga, additional, Bekiari, Eleni, additional, Liakos, Aris, additional, Iatridi, Fotini, additional, Paschos, Paschalis, additional, Sinakos, Emmanouil, additional, and Tsapas, Apostolos, additional

Published
2024
Full Text
View/download PDF

3. Testosterone and dihydrotestosterone modulate the redox homeostasis of endothelium

Author

George N. Koukoulis, Maria Filiponi, Sofia Gougoura, Christina Befani, Panagiotis Liakos, and Αlexandra Bargiota

Subjects
Male, Homeostasis, Humans, Dihydrotestosterone, Female, Testosterone, Endothelium, Endothelium, Vascular, Cell Biology, General Medicine, Nitric Oxide, Oxidation-Reduction
Abstract

The predominance of cardiovascular diseases among men compared to premenopausal women has been attributed to testosterone, which is implicated in vascular remodeling. Molecular mechanisms underlying its role have not been clarified but oxidative stress-induced inflammation may be important. We therefore investigated in vitro the effects of testosterone and dihydrotestosterone, (a nonaromatized androgen), on redox homeostasis in absence (basal conditions) and after corticotropin-releasing hormone-induced pro-oxidant action in macroendothelial cells. More specifically, we explored their role on well-established antioxidant enzymes activity, namely endothelial nitric oxide synthase, superoxide dismutase, catalase, and glutathione. We observed that both androgens significantly increased the intracellular reactive oxygen species levels, endothelial nitric oxide synthase activity, nitric oxide concentration as well as superoxide dismutase activity and decreased catalase activity. These effects of Testosterone and DHT were reversed in the presence of the androgen receptor antagonist, flutamide. Moreover, testosterone and dihydrotestosterone similarly enhanced the stimulatory effect of corticotropin-releasing hormone on intracellular reactive oxygen species levels and superoxide dismutase activity but did not influence the inhibitory effect on endothelial nitric oxide synthase activity, nitric oxide release and catalase activity. Finally, androgens did not have a detectable effect on glutathione levels or the glutathione/glutathione plus glutathione disulfide ratio. Our results reveal that testosterone and DHT rise the intracellular redox threshold of the endothelial cell and increases NO synthesis. These findings suggest that the action of testosterone is affected by the redox status of the endothelium and help to explain its controversial effects on the cardiovascular system.

Published
2022
Full Text
View/download PDF

4. Sotagliflozin for patients with type <scp>2</scp> diabetes: A systematic review and meta‐analysis

Author

David R. Matthews, Panagiota Kakotrichi, Thomas Karagiannis, Eleni Bekiari, Aris Liakos, Ioannis Avgerinos, Theodoros Michailidis, and Apostolos Tsapas

Subjects
medicine.medical_specialty, Diabetic ketoacidosis, business.industry, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Cochrane Library, medicine.disease, Placebo, law.invention, Endocrinology, Blood pressure, Diabetes Mellitus, Type 2, Randomized controlled trial, law, Internal medicine, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, Glycosides, Myocardial infarction, business, Sodium-Glucose Transporter 2 Inhibitors, Stroke
Abstract

Aim To assess the efficacy and safety of sotagliflozin in patients with type 2 diabetes mellitus. Methods We searched Medline, Embase, the Cochrane Library, and grey literature sources up to August 2021 for randomized controlled trials (RCTs) that compared sotagliflozin with placebo or other antidiabetic agents in patients with type 2 diabetes. Our primary outcome was change in HbA1c from baseline. We additionally assessed 3 secondary efficacy and 15 safety outcomes. We synthesized data using weighted mean differences (WMDs) and odds ratios (ORs), along with 95% confidence intervals (CIs). Findings We included 11 RCTs comprising 16411 subjects in the meta-analysis. Compared with placebo, sotagliflozin reduced HbA1c (WMD -0.42 %, 95% CI -0.56 to -0.29), body weight (WMD -1.33 kg, 95% CI -1.57 to -1.09) and systolic blood pressure (WMD -2.44 mmHg, 95% CI -2.81 to -2.07). No difference was evident against other active comparators. Sotagliflozin reduced myocardial infarction (OR 0.72, 95% CI 0.54 to 0.97) and heart failure (OR 0.68, 95% CI 0.58 to 0.79) compared with placebo, and had a neutral effect on all-cause mortality, cardiovascular mortality, and stroke. Treatment with sotagliflozin was safe regarding incidence of serious adverse events, hypoglycaemia, and diabetic ketoacidosis. Nevertheless, it was associated with increased incidence of diarrhoea, genital infections, and volume depletion events. Conclusions Sotagliflozin reduces blood glucose, body weight and systolic blood pressure, and demonstrates a beneficial effect on heart failure and myocardial infarction. Its overall safety profile is comparable to other SGLT-2 inhibitors. This article is protected by copyright. All rights reserved.

Published
2021
Full Text
View/download PDF

8. Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis

Author

Maria Mainou, Thomas Karagiannis, Theodoros Michailidis, David R. Matthews, Aris Liakos, Eleni Bekiari, Apostolos Tsapas, Georgia Papanastasiou, and Ioannis Avgerinos

Subjects
Adult, Blood Glucose, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Diabetes mellitus, Internal medicine, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, Insulin Aspart, Glycated Hemoglobin, Type 1 diabetes, business.industry, medicine.disease, Confidence interval, Postprandial, Diabetes Mellitus, Type 2, Basal (medicine), Meta-analysis, business
Abstract

We performed a systematic review and meta-analysis of randomized controlled trials to assess the efficacy and safety of the novel, ultra-rapid acting insulins aspart and lispro in adults with type 1 or type 2 diabetes. Our primary outcome was change in HbA1c from baseline. We additionally assessed eight efficacy and six safety endpoints. We calculated weighted mean differences (WMD) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, alongside 95% confidence intervals (CIs). We additionally assessed statistical heterogeneity among studies with the I2 statistic, considering values greater than 60% indicative of substantial heterogeneity. Nine studies comprising 5931 patients were included in the systematic review; eight active-controlled studies could be synthesized in terms of a meta-analysis. Treatment with ultra-rapid acting insulins had a similar effect on change in HbA1c, compared with rapid-acting insulins (WMD -0.02 %, 95% CI -0.08 to 0.05, I2 =61% for patients with type 1 diabetes and -0.02 %, 95% CI -0.09 to 0.04, I2 =19% for patients with type 2 diabetes). Similarly, no difference was evident in terms of change in fasting plasma glucose, self-measured plasma glucose, body weight, basal or bolus insulin dose, incidence of serious adverse events and hypoglycaemia. Compared with rapid-acting insulins, ultra-rapid insulins reduced 1-hour and 2-hour postprandial glucose (PPG) increment based on a liquid meal test, both in patients with type 1 and type 2 diabetes (WMD -0.94 mmol/L, 95% CI -1.17 to -0.72, I2 =0% and -0.56 mmol/L, 95% CI -0.79 to -0.32, I2 =0%, respectively for change in 1-hour PPG increment). In conclusion, ultra-rapid acting insulins were as efficacious and safe as rapid-acting insulins, demonstrating a favourable effect solely on PPG control. This article is protected by copyright. All rights reserved.

Published
2021
Full Text
View/download PDF

9. Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis

Author

Apostolos Tsapas, Panagiota Kakotrichi, Thomas Karagiannis, Apostolos Manolopoulos, Konstantinos Malandris, Aris Liakos, Ioannis Avgerinos, Georgios Tousinas, Eleni Bekiari, David R. Matthews, and Chrysanthi Mantsiou

Subjects
Adult, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Network Meta-Analysis, Blood Pressure, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Internal medicine, Internal Medicine, medicine, Empagliflozin, Humans, Hypoglycemic Agents, Dapagliflozin, Canagliflozin, Liraglutide, business.industry, Semaglutide, Body Weight, medicine.disease, Glucose, Blood pressure, Diabetes Mellitus, Type 2, chemistry, business, Exenatide, medicine.drug
Abstract

Aim To compare the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes. Methods We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes. We performed frequentist network meta-analyses and calculated weighted mean differences and 95% confidence intervals combining trial arms of different approved doses of a given intervention into a single group. We evaluated the confidence in pooled estimates using the CINeMA (Confidence In Network Meta-Analysis) framework. Results In total, 424 trials (276 336 patients) assessing 21 antidiabetic medications from nine drug classes were included. Subcutaneous semaglutide was the most efficacious in reducing body weight followed by oral semaglutide, exenatide twice-daily, liraglutide, and the sodium-glucose co-transporter-2 (SGLT-2) inhibitors empagliflozin, canagliflozin, dapagliflozin and ertugliflozin. The same agents also conferred the greatest reductions in systolic blood pressure. Metformin had a modest effect in reducing body weight and systolic blood pressure. Diastolic blood pressure was reduced with the SGLT-2 inhibitors pioglitazone, exenatide twice-daily and semaglutide. In subgroup analyses of trials with over 52 weeks' duration, semaglutide and SGLT-2 inhibitors reduced both body weight and systolic blood pressure. Conclusions Semaglutide and SGLT-2 inhibitors conferred reductions both in body weight and blood pressure that were sustainable for over 1 year of treatment. These agents may be preferable treatment options for patients with type 2 diabetes who are overweight/obese and/or hypertensive.

Published
2021
Full Text
View/download PDF

10. Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta‐analysis

Author

Apostolos Manolopoulos, David R. Matthews, Ioannis Avgerinos, Eleni Bekiari, Apostolos Tsapas, Aris Liakos, Thomas Karagiannis, Konstantinos Dimitrakopoulos, Theodoros Michailidis, and Konstantinos Kitsios

Subjects
Adult, medicine.medical_specialty, Diabetic ketoacidosis, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Network Meta-Analysis, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Internal Medicine, Empagliflozin, medicine, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Type 1 diabetes, Liraglutide, business.industry, Insulin, medicine.disease, Pramlintide, Metformin, Diabetes Mellitus, Type 1, Glucose, Pharmaceutical Preparations, business, Exenatide, medicine.drug
Abstract

Aim To assess the efficacy and safety of glucose-lowering drugs used as adjunct to insulin therapy in adults with type 1 diabetes. Methods We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials up to January 24, 2020 for randomised controlled trials. Our primary outcome was change in HbA1c . We additionally assessed 8 efficacy and 6 safety secondary endpoints. We performed random-effects frequentist network meta-analysis to estimate mean differences (MDs) and odds ratios (ORs), alongside 95% confidence intervals (CIs). We assessed risk of bias and evaluated confidence in the evidence for the primary outcome. Results We included 58 trials comprising 13 216 participants. Overall, sodium-glucose co-transporter (SGLT) inhibitors, liraglutide, glibenclamide, acarbose and metformin reduced HbA1c compared with placebo (MDs ranging from -0.46% [95% CI -0.64 to -0.29] for empagliflozin to -0.20% [-0.35 to -0.06] for metformin). SGLT inhibitors, exenatide daily, liraglutide, and metformin reduced body weight and total daily insulin dose, while liraglutide and SGLT inhibitors reduced blood pressure. Diabetic ketoacidosis and genital infections were more frequent with SGLT inhibitors, while exenatide, liraglutide, pramlintide and metformin increased odds of nausea. No drug increased odds of severe hypoglycaemia. Confidence in evidence was mainly moderate to very low. Conclusions Specific drugs may improve glycaemic control and reduce body weight, blood pressure and total daily insulin dose in patients with type 1 diabetes. However low quality of evidence and increased risk of diabetic ketoacidosis, genital infections or gastrointestinal adverse events should be taken into consideration by healthcare providers and patients. Future long-term trials are needed to clarify their benefit-to-risk profile and elucidate their role in clinical practice. This article is protected by copyright. All rights reserved.

Published
2021
Full Text
View/download PDF

12. Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Author

Panagiota Kakotrichi, Thomas Karagiannis, Ioannis Avgerinos, Eleni Bekiari, Aris Liakos, Apostolos Tsapas, Konstantinos Malandris, and Chrysanthi Mantsiou

Subjects
medicine.medical_specialty, Combination therapy, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Gastroenterology, Glucagon-Like Peptide-1 Receptor, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Myocardial infarction, Sodium-Glucose Transporter 2 Inhibitors, Stroke, Symporters, business.industry, Sodium, medicine.disease, Glucose, Blood pressure, Diabetes Mellitus, Type 2, Heart failure, business
Abstract

Aim To assess the efficacy and safety of combination therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a sodium-glucose co-transporter-2 inhibitor (SGLT2i) in patients with type 2 diabetes. Methods We searched Medline, Embase, the Cochrane Library and grey literature sources up to 2 December 2019 for randomized controlled trials in adults with type 2 diabetes assessing the combination of GLP-1RA and SGLT2i, either as co-initiation therapy or as add-on to each other, against placebo or an active comparator. The primary outcome was change in HbA1c . Secondary outcomes included change in body weight, blood pressure and estimated glomerular filtration rate, and incidence of severe hypoglycaemia, all-cause mortality, cardiovascular mortality, myocardial infarction, stroke and hospitalization for heart failure. We pooled data using random effects meta-analyses. Results Seven trials (1913 patients) were eligible. Compared with GLP-1RA, GLP-1RA/SGLT2i combination therapy was associated with a greater reduction in HbA1c (weighted mean difference -0.61%, 95% CI -1.09% to -0.14%, four studies), body weight (-2.59 kg, -3.68 to -1.51 kg, three studies) and systolic blood pressure (-4.13 mmHg, -7.28 to -0.99 mmHg, four studies). Compared with SGLT2i, GLP-1RA/SGLT2i combination therapy reduced HbA1c (-0.85%, -1.19% to -0.52%, six studies) and systolic blood pressure (-2.66 mmHg, -5.26 to -0.06 mmHg, six studies), but not body weight (-1.46 kg, -2.94 to 0.03 kg, five studies). After excluding data for one trial that had a considerably longer duration than the remaining studies, body weight was also reduced versus SGLT2i (-1.79 kg, -2.99 to -0.59 kg, five studies). Combination therapy did not increase the incidence of severe hypoglycaemia. Data for mortality and cardiovascular outcomes were scarce. Conclusions GLP-1RA/SGLT2i combination therapy seems to reduce HbA1c , body weight and systolic blood pressure without increasing the risk of severe hypoglycaemia compared with either GLP-1RA or SGLT2i. No conclusions can be made regarding long-term effectiveness or the effect on cardiovascular outcomes.

Published
2020
Full Text
View/download PDF

13. Surgeons' fear of getting infected by COVID19: A global survey

Author

An, Y., Bellato, V., Konishi, T., Pellino, G., Sensi, B., Siragusa, L., Franceschilli, M., Sica, G. S., Kefleyesus, A., Hoofwijk, A. G. M., Eldaly, A. S., Gonzalez, A., Jawad, A., Jooma, A., Hafez, A. M., Rubio, A. V., Landaluce-Olavarria, A., Wu, A., Nagatsu, A., Inoue, A., Kanamoto, A., Ouchi, A., El-Hussuna, A., Vazquez-Melero, A., Wolthuis, A. M., Peral, A. M., Lozano, A. C., Efremov, A., Ryasantsev, A. V., Giorgio, A. D., Parente, A., Tamburrini, A., Alo, A., Forero-Torres, A., Vahrmeijer, A. L., Varabei, A., Hinojosa, S., Balkan, A. Z. A., Frontali, A., Oleg, A., Soler-Silva, A., Makni, A., Andre, A., Cabrera, A. M. G., Fernandez, A. M. G., Minaya-Bravo, A. M., Rodriguez-Sanchez, A., Musina, A. -M., Pangeni, A., Zolotko, A., Tonoyan, A., Balla, A., Belli, A., Cavallaro, A., Chierici, A., Divizia, A., Bucci, A. F., Salido, A. J., Morini, A., Muratore, A., Vignali, A., Chitul, A., Sebastian, D. A., Pcolkins, A., Shchegolev, A., Hollenbeck, A., Wisneski, A., Iossa, A., D'Amore, A., Hunter, A., Hesketh, A. J., Brocca, A. L., Spinelli, A., Caires, A., D'Alessandro, A., Correo, A. F. S. L., Macri, A., Navarro-Sanchez, A., Pronk, A., Akunc, A., Mehri, A., Pelta, A., Papadopoulos, A., Kechagias, A., Rashid, A., Ramazanov, A., Chandio, A., Kohyama, A., Nishimura, A., Ohkawa, A., Dulskas, A., Jamal, A., Mariani, A., Unal, A. G., Karagoz, A., Ozkan, B. B., Salih, B., Gulcu, B., Pessia, B., Martin-Perez, B., Ielpo, B., Tulelli, B., Yang, B., Mhamed, B., Murphy, B., Pirozzi, B. M., Langenhoff, B., Belevi, B., Guney, B., Ng, C., Rueda, C., Roxburgh, C. S., Feo, C. V., Ferrari, C., Gazia, C., Pratesi, C., Ratto, C., Santacruz, C. C., Arroyave, C. R. M., Macias, C., Fernandez, C. G., Fernandez, C. C., Curtis-Martinez, C., Fortmann, C., Kim, C., Galeano, C. U., Barroso, C., Baldi, C., Foppa, C., Formisano, C., Li, C., Ding, C., Wang, C., Iacusso, C., Yang, C., Pizzera, C., Skias, C., Chouliras, C., Liakos, C., Matsuda, C., C. -Y., Wu, Ozaslan, C., Tanda, C., Tommaso, C. M., Dagorno, C., Ramos, C. P. A., Arcudi, C., Coco, C., Morales, C. M., Ali, M. Z., De Azevedo, C. T. M., Lozano, C. C., Sala, C., Leo, C. A., Scarpa, C. R., Ferro, C. V., Fernandez, C. M., Morales-Garcia, D., Nakano, D., Cristian, D., Hechtl, D., Canovas, D. T., Calabrese, D., Rega, D., Ferraro, D., Morezzi, D., Sommacale, D., Brogden, D., Miskovic, D., Merlini, D., Pertile, D., Coniglio, D., Zhu, D., Wu, D., Coletta, D., Rubio, D. R., Sasia, D., Fillipov, D., Russiello, D., Dardanov, D., Consten, E. C. J., Smolskas, E., Muttillo, E. M., Jones, E., Sunami, E., Etienne, E. -H., Chalkiadaki, E., Giacomelli, E., Karbovnichaya, E., Ruiz-Ucar, E., Guaitoli, E., Samadov, E., Jovine, E., Treppiedi, E., Vaterlini, E. M., Zambaiti, E., Moggia, E., Coetzee, E., Chisari, E., D'Errico, E., Ciofic, E., Pena, E., Kurt, E., Balik, E., Gunay, E., Sivrikoz, E., Andolfi, E., Araimo, E., Lucci, E., Opocher, E., Pinotti, E., Rubino, E., Reyhan, E., Mazzotta, E., Navarro, E. B., El-Helou, E., Licardie-Bolanos, E., Porto, E. I., Contreras, E., Boerma, E. -J., Cianchi, F., Marino, F., Uggeri, F., Han, F., Calculli, F., Falaschi, F., Ghignone, F., Perrone, F., Borghi, F., Garcia, F., Agresta, F., Cananzi, F. C. M., Mendoza-Moreno, F., Cengiz, F., Almeida, F. M., Baracchi, F., Carannante, F., Torre, F. L., Fernandes, F., Friedmacher, F., Grama, F., Carissimi, F., Pecchini, F., Bianco, F., Colombo, F., Ferrara, F., Litta, F., Carrano, F. M., Martignoni, F., Tasselli, F. M., Milone, F., Pata, F., Sammartino, F., Zambianchi, F., Barragan, F., Herrero, F., Schlottmann, F., Den Boer, F. C., Pfeffer, F., Fujita, F., Navarra, G., Herrera-Almario, G., Pozzo, G., Capolupo, G. T., Van Ramshorst, G. H., Liscia, G., Gallo, G., Asawa, G., Wang, G., Raiyani, G., Beets, G., Naval, G. S., Jin, G., Chang, G. J., Saakian, G., Kahane, G., Borroni, G., Secco, G. L., Baiocchi, G. L., Baronio, G., Pagano, G., Pattacini, G. C., Lisi, G., Milito, G., Sinibaldi, G., Serrao, G., Bagaglini, G., Sarro, G., Brisinda, G., Candilio, G., Mangiameli, G., Giuliani, G., Martin-Martin, G. P., Bodzin, G., Leon, G., Mackay, G., Vasil, G., Palmisano, G., Giovanna, G. M., Fernandez, G. C., Steingel, G. B., Zhang, G., Choi, G. S., Chen, H., Hirose, H., Kayano, H., Ulgur, H. S., Impellizzeri, H., Ariola, H., Liu, H., Medina, H., Miyauchi, H., Takahashi, H., Hayashi, H., Ishikawa, H., Ishida, H., De Vries, H., Ulman, H., Kon, H., Ota, H., Akamatsu, H., Tamagawa, H., Shoji, H., Egi, H., Matsubara, H., Miki, H., Elfeki, H., Lin, H. -H., Giani, I., Caravaca-Garcia, I., Takemasa, I., Angriman, I., Negoi, I., Volkova, I., Russo, I., Kronberger, I. E., Shageev, I., Aydin, I., Guzman, I. M., Novak, I., Giuliano, I., Rachmuth, J., Ngu, J. C. -Y., Glasbey, J., Stoot, J., Zatecky, J., Melenhorst, J., Van Der Wal, J. B. C., Leijtens, J., Bogach, J., Elliott, J., De Wilt, J. H. W., Han, J., Cui, J., Liu, J., Khan, J., Wirawan, J. P., Zhang, J., Manyari, J. D. O., Doerner, J., Bock, J., Konsten, J., Castro, J. M., Grobas, J. P., Pinto, J. P., Juloski, J., Laina, J. L. B., Solorzano, J. J., Lopez, J. R. G., Li, J., Watanabe, J., Kwak, J. -M., Hasegawa, J., Hiro, J., Sergey, K., Zhang, K., Nagahori, K., Martinez, K., Tokuhara, K., Danno, K., Uehara, K., Yoshimatsu, K., Ehara, K., Ueda, K., Suda, K., Yamamoto, K., Ishimaru, K., Kimura, K., Hirata, K., Deen, K., Imaizumi, K., Yamada, J., Tanakura, K., Rida, K., Sugimoto, K., Kotaro, K., Shi, K., Okabayashi, K., Hida, K., Kataoka, K., Hongo, K., Xia, K., Tseng, L., Reime, L., Lorenzon, L., Ruano, L. M., Zhou, L., De Nes, L., Brandariz, L., Morini, L., Petagna, L., Ripamonti, L., Martinez, L. H., Pio, L., Sacco, L., Carvalho, L., Zorcolo, L., Perez-Sanchez, L. E., Esparza, L. H. R., Aguilar, L. T., Garner, M., Sugimoto, M., Nagashima, M., Shiozawa, M., Simone, M., Ferrer-Marquez, M., Carvalho, M., Alifano, M., Arganini, M., Calussi, M., Catarci, M., Allaix, M. E., Forlin, M., Milone, M., Paci, M., Fodor, M., Antipova, M., Martos, M. B., Giuffrida, M. C., Tabernilla, M. D., Quiros, M. J. A., Lemma, M., Correo, M. L. R. D., Malowiecka, M., Bellomo, M. P., Fernandez, M. R., Socias, M., Rizk, M., Aurora, M., Antolinez, M. A., Ninkovic, M., Giuffrida, M., Leeuwenburgh, M. M. N., De Roos, M. A. J., Lara, M. C., Agustin, M. C., Cuadrado, M., Pascual, M., Lemmerer, M., Carlos, R., Okamoto, M., Miyo, M., Inomata, M., Ikenaga, M., Tsujie, M., Yasuno, M., Kotake, M., Sato, M., Yasui, M., Lavazza, M., Rottoli, M., Zuin, M., Zuluaga, M., Cervellera, M., Cesari, M., Zizzo, M., Garino, M., Ghirardi, M., Montuori, M., Podda, M., Santarelli, M., Koc, M. A., Baini, M., De Cillia, M., Campanelli, M., De Rosa, M., Manigrasso, M., Zuolo, M., Cunha, M. F., Misca, M., Slavchev, M., Danilov, M., Shigaev, M., Martens, M., Kobayashi, M., Ren, M., Ishizuka, M., Hassan, M. M., Siblini, M., Sahloul, M., Keramati, M. R., Karunakaran, M., Markel, M., Majeed, M., Younis, M. U., Akin, M. I., Laraibe, M., Derebey, M., Kendirci, M., Fukunaga, M., Matsubara, N., Ordaz, N. E. C., Samalavicius, N. E., Keeratibharat, N., De Angelis, N., Gica, N., Mariani, N. M., Ramino, N., Falco, N., Smart, N., De Korte, N., Kok, N. F. M., Jamieson, N. B., Aberyasev, N., Bruklich, N., Ichikawa, N., Miyoshi, N., De Palma, N., Figueiredo, N., Torrecilla, N. O., Dybov, O. G., Yudin, O., Crepin, O., Gomez, O., Sert, O. Z., Lominchar, P. L., Menendez, P., De Nardi, P., Tejedor, P., Jordan, P., Tan, P., Marsanic, P., Natalya, P., Banos, P. P., Rebasa, P., Neary, P. M., Tanis, P., Giustacchini, P., Anoldo, P., Concejo, P., Cao, P., Chandrasinghe, P., Abeyratne, P., Wang, Q., Klicks, R. J., Mukai, R., Riquelme, R. F., De Luca, R., Galli, R., Gianesini, R., Moorjani, R. G., Deshpande, R. K., Gorter, R., Ledesma, R. L., Ruslan, R., Chhabra, R., Talreja-Pelaez, R., Suzuki, R., Balestri, R., Rosati, R., Kiblawi, R., Martins, R., Angelico, R., Tutino, R., Persiani, R., Pollastri, R., Lopez, R. G., Perez, R. O., Hompes, R., Lukanin, R., Roser Termes Serra, R., Brunaccino, R., Nakanishi, R., Stefan, S., Hernandez, S. P. S., Carlo, S. D., Ingallinella, S., Domoto, S., Ikeda, S., Mikalauskas, S., Kim, S. H., Mantova, S., Barbuta, S., Li, S., Yamaguchi, S., Yamagishi, S., Homma, S., Tsujinaka, S., Yoshioka, S., Mori, S., Tewari, S., Rayman, S., Horiuchi, S., Matoba, S., Morita, S., Yaman, S., Vigna, S., Testa, S., Ng, S., Deidda, S., Cicconi, S., Maria, S. D., Sibio, S., Ersoz, S., Pejkova, S., Altarifi, S., He, S., Malakorn, S., Meindert, S., Sumikawa, S., Parmar, S., Uranitsch, S., D'Ugo, S., Giuliani, S., Breukink, S., Lee, S. -H., Hata, T., Ishikawa, T., Akiyoshi, T., Azuma, T., Kobatake, T., Fukuzaki, T., Aiyama, T., Yamada, T., Garmanova, T., Gomez-Sanchez, T., Yamaguchi, T., De Jesus Flores, T., Usub, T., Tsuruma, T., Shimizu, T., Hristov, T. G., Van Loon, T., Funakoshi, T., Manzia, T. M., Kiyomatsu, T., Katayama, T., Akagi, T., Mizushima, T., Kazuhito, U., Elmore, U., Grossi, U., Truchalev, V. A., Rodriguez, V. S., Testa, V., Tonini, V., Celentano, V., Nekoval, V. M., Bettencourt, V., Mammadov, V., Leyva, V. A. G., Mariscal, V. G. O., Seid, V. E., Klemann, V., Turrado-Rodriguez, V., Papagni, V., Vento, V., Frering, V., Vigorita, V., Petrove, V. V., Lyadov, V., Fu, W., Mi, W., Jeong, W. K., Leclercq, W. K. G., De Sousa, X., Zhao, X., Li, X., Wang, X., Yang, X., Zhang, X., Zhen, Y., Dong, Y., Erushevich, Y., Takii, Y., Sumi, Y., Loli, Y. T., Yifat, Y. L., Shimada, Y., Nabeya, Y., Ide, Y., Wu, Y., Tsukada, Y., Miyamoto, Y., Toiyama, Y., Fujie, Y., Kaneko, Y., Mokutani, Y., Fujii, Y., Kanemitsu, Y., Medkova, Y., Chen, Y., Ruiz, Y. G., Kinugasa, Y., Sow, Z., Razzaq, Z., Wang, Z., Liu, Z., Han, Z., Tai, Z., Lai, Z., Z. Q., Ng, Dambrauskas, Z., An Y., Bellato V., Konishi T., Pellino G., Sensi B., Siragusa L., Franceschilli M., Sica G.S., Kefleyesus A., Hoofwijk A.G.M., Eldaly A.S., Gonzalez A., Jawad A., Jooma A., Hafez A.M., Rubio A.V., Landaluce-Olavarria A., Wu A., Nagatsu A., Inoue A., Kanamoto A., Ouchi A., El-Hussuna A., Vazquez-Melero A., Wolthuis A.M., Peral A.M., Lozano A.C., Efremov A., Ryasantsev A.V., Di Giorgio A., Parente A., Tamburrini A., Alo A., Forero-Torres A., Vahrmeijer A.L., Varabei A., Hinojosa S., Balkan A.Z.A., Frontali A., Oleg A., Soler-Silva A., Makni A., Andre A., Cabrera A.M.G., Fernandez A.M.G., Minaya-Bravo A.M., Rodriguez-Sanchez A., Musina A.-M., Pangeni A., Zolotko A., Tonoyan A., Balla A., Belli A., Cavallaro A., Chierici A., Divizia A., Bucci A.F., Salido A.J., Morini A., Muratore A., Vignali A., Chitul A., Sebastian D.A., Pcolkins A., Shchegolev A., Hollenbeck A., Wisneski A., Iossa A., D'Amore A., Hunter A., Hesketh A.J., La Brocca A., Spinelli A., Caires A., D'Alessandro A., Correo A.F.S.L., Macri A., Navarro-Sanchez A., Pronk A., Akunc A., Mehri A., Pelta A., Papadopoulos A., Kechagias A., Rashid A., Ramazanov A., Chandio A., Kohyama A., Nishimura A., Ohkawa A., Dulskas A., Jamal A., Mariani A., Unal A.G., Karagoz A., Ozkan B.B., Salih B., Gulcu B., Pessia B., Martin-Perez B., Ielpo B., Tulelli B., Yang B., Mhamed B., Murphy B., Pirozzi B.M., Langenhoff B., Belevi B., Guney B., Ng C., Rueda C., Roxburgh C.S., Feo C.V., Ferrari C., Gazia C., Pratesi C., Ratto C., Santacruz C.C., Arroyave C.R.M., Macias C., Fernandez C.G., Fernandez C.C., Curtis-Martinez C., Fortmann C., Kim C., Galeano C.U., Barroso C., Baldi C., Foppa C., Formisano C., Li C., Ding C., Wang C., Iacusso C., Yang C., Pizzera C., Skias C., Chouliras C., Liakos C., Matsuda C., Wu C.-Y., Ozaslan C., Tanda C., Tommaso C.M., Dagorno C., Ramos C.P.A., Arcudi C., Coco C., Morales C.M., Ali M.Z., Lozano C.C., Sala C., Leo C.A., Scarpa C.R., Ferro C.V., Fernandez C.M., Morales-Garcia D., Nakano D., Cristian D., Hechtl D., Canovas D.T., Calabrese D., Rega D., Ferraro D., Morezzi D., Sommacale D., Brogden D., Miskovic D., Merlini D., Pertile D., Coniglio D., Zhu D., Wu D., Coletta D., Rubio D.R., Sasia D., Fillipov D., Russiello D., Dardanov D., Consten E.C.J., Smolskas E., Muttillo E.M., Jones E., Sunami E., Etienne E.-H., Chalkiadaki E., Giacomelli E., Karbovnichaya E., Ruiz-Ucar E., Guaitoli E., Samadov E., Jovine E., Treppiedi E., Vaterlini E.M., Zambaiti E., Moggia E., Coetzee E., Chisari E., D'Errico E., Ciofic E., Pena E., Kurt E., Balik E., Gunay E., Sivrikoz E., Andolfi E., Araimo E., Lucci E., Opocher E., Pinotti E., Rubino E., Reyhan E., Mazzotta E., Navarro E.B., El-Helou E., Licardie-Bolanos E., Porto E.I., Contreras E., Boerma E.-J., Cianchi F., Marino F., Uggeri F., Han F., Calculli F., Falaschi F., Ghignone F., Perrone F., Borghi F., Garcia F., Agresta F., Cananzi F.C.M., Mendoza-Moreno F., Cengiz F., Almeida F.M., Baracchi F., Carannante F., La Torre F., Fernandes F., Friedmacher F., Grama F., Carissimi F., Pecchini F., Bianco F., Colombo F., Ferrara F., Litta F., Carrano F.M., Martignoni F., Tasselli F.M., Milone F., Pata F., Sammartino F., Zambianchi F., Barragan F., Herrero F., Schlottmann F., Den Boer F.C., Pfeffer F., Fujita F., Navarra G., Herrera-Almario G., Pozzo G., Capolupo G.T., Van Ramshorst G.H., Liscia G., Gallo G., Asawa G., Wang G., Raiyani G., Beets G., Naval G.S., Jin G., Chang G.J., Saakian G., Kahane G., Borroni G., Secco G.L., Baiocchi G.L., Baronio G., Pagano G., Pattacini G.C., Lisi G., Milito G., Sinibaldi G., Serrao G., Bagaglini G., Sarro G., Brisinda G., Candilio G., Mangiameli G., Giuliani G., Martin-Martin G.P., Bodzin G., Leon G., Mackay G., Vasil G., Palmisano G., Giovanna G.M., Fernandez G.C., Steingel G.B., Zhang G., Choi G.S., Chen H., Hirose H., Kayano H., Ulgur H.S., Impellizzeri H., Ariola H., Liu H., Medina H., Miyauchi H., Takahashi H., Hayashi H., Ishikawa H., Ishida H., De Vries H., Ulman H., Kon H., Ota H., Akamatsu H., Tamagawa H., Shoji H., Egi H., Matsubara H., Miki H., Elfeki H., Lin H.-H., Giani I., Caravaca-Garcia I., Takemasa I., Angriman I., Negoi I., Volkova I., Russo I., Kronberger I.E., Shageev I., Aydin I., Mora Guzman I., Novak I., Giuliano I., Rachmuth J., Ngu J.C.-Y., Glasbey J., Stoot J., Zatecky J., Melenhorst J., Van Der Wal J.B.C., Leijtens J., Bogach J., Elliott J., De Wilt J.H.W., Han J., Cui J., Liu J., Khan J., Wirawan J.P., Zhang J., Manyari J.D.O., Doerner J., Bock J., Konsten J., Castro J.M., Grobas J.P., Pereira J., Juloski J., Laina J.L.B., Solorzano J.J., Lopez J.R.G., Li J., Watanabe J., Kwak J.-M., Hasegawa J., Hiro J., Sergey K., Zhang K., Nagahori K., Martinez K., Tokuhara K., Danno K., Uehara K., Yoshimatsu K., Ehara K., Ueda K., Suda K., Yamamoto K., Ishimaru K., Kimura K., Hirata K., Deen K., Imaizumi K., Yamada J., Tanakura K., Rida K., Sugimoto K., Kotaro K., Shi K., Okabayashi K., Hida K., Kataoka K., Hongo K., Xia K., Tseng L., Reime L., Lorenzon L., Ruano L.M., Zhou L., De Nes L., Brandariz L., Morini L., Petagna L., Ripamonti L., Martinez L.H., Pio L., Sacco L., Carvalho L., Zorcolo L., Perez-Sanchez L.E., Esparza L.H.R., Aguilar L.T., Garner M., Sugimoto M., Nagashima M., Shiozawa M., Simone M., Ferrer-Marquez M., Carvalho M., Alifano M., Arganini M., Calussi M., Catarci M., Allaix M.E., Forlin M., Milone M., Paci M., Fodor M., Antipova M., Martos M.B., Giuffrida M.C., Tabernilla M.D., Quiros M.J.A., Lemma M., Correo M.L.R.D., Malowiecka M., Bellomo M.P., Fernandez M.R., Socias M., Rizk M., Aurora M., Antolinez M.A., Ninkovic M., Giuffrida M., De Roos M.A.J., Lara M.C., Agustin M.C., Cuadrado M., Pascual M., Lemmerer M., Carlos R., Okamoto M., Miyo M., Inomata M., Ikenaga M., Tsujie M., Yasuno M., Kotake M., Sato M., Yasui M., Lavazza M., Rottoli M., Zuin M., Zuluaga M., Cervellera M., Cesari M., Zizzo M., Garino M., Ghirardi M., Montuori M., Podda M., Santarelli M., Koc M.A., Baini M., Campanelli M., Manigrasso M., Zuolo M., Cunha M.F., Misca M., Slavchev M., Danilov M., Shigaev M., Martens M., Kobayashi M., Ren M., Ishizuka M., Hassan M.M., Siblini M., Sahloul M., Keramati M.R., Karunakaran M., Markel M., Majeed M., Younis M.U., Akin M.I., Laraibe M., Derebey M., Kendirci M., Fukunaga M., Matsubara N., Ordaz N.E.C., Samalavicius N.E., Keeratibharat N., de Angelis N., Gica N., Mariani N.M., Ramino N., Falco N., Smart N., De Korte N., Kok N.F.M., Jamieson N.B., Aberyasev N., Bruklich N., Ichikawa N., Miyoshi N., De Palma N., Figueiredo N., Torrecilla N.O., Dybov O.G., Yudin O., Crepin O., Gomez O., Sert O.Z., Lominchar P.L., Menendez P., De Nardi P., Tejedor P., Jordan P., Tan P., Marsanic P., Natalya P., Banos P.P., Rebasa P., Neary P.M., Tanis P., Giustacchini P., Anoldo P., Concejo P., Cao P., Chandrasinghe P., Abeyratne P., Wang Q., Klicks R.J., Riquelme R.F., Galli R., Gianesini R., Moorjani R.G., Deshpande R.K., Gorter R., Ledesma R.L., Ruslan R., Chhabra R., Talreja-Pelaez R., Suzuki R., Balestri R., Rosati R., Kiblawi R., Martins R., Angelico R., Tutino R., Persiani R., Pollastri R., Lopez R.G., Perez R.O., Hompes R., Lukanin R., Roser Termes Serra R., Brunaccino R., Nakanishi R., Stefan S., Hernandez S.P.S., Di Carlo S., Ingallinella S., Domoto S., Ikeda S., Mikalauskas S., Kim S.H., Mantova S., Barbuta S., Li S., Yamaguchi S., Yamagishi S., Homma S., Tsujinaka S., Yoshioka S., Mori S., Tewari S., Rayman S., Horiuchi S., Matoba S., Morita S., Yaman S., Vigna S., Testa S., Ng S., Deidda S., Cicconi S., Di Maria S., Sibio S., Ersoz S., Pejkova S., Altarifi S., He S., Malakorn S., Meindert S., Sumikawa S., Parmar S., Uranitsch S., D'ugo S., Giuliani S., Breukink S., Lee S.-H., Hata T., Ishikawa T., Akiyoshi T., Azuma T., Kobatake T., Fukuzaki T., Aiyama T., Yamada T., Garmanova T., Gomez-Sanchez T., Yamaguchi T., Flores T.D.J., Usub T., Tsuruma T., Shimizu T., Hristov T.G., Van Loon T., Funakoshi T., Manzia T.M., Kiyomatsu T., Katayama T., Kazuhito U., Elmore U., Grossi U., Truchalev V.A., Rodriguez V.S., Testa V., Tonini V., Celentano V., Bettencourt V., Mammadov V., Leyva V.A.G., Mariscal V.G.O., Seid V.E., Klemann V., Turrado-Rodriguez V., Papagni V., Vento V., Frering V., Vigorita V., Petrove V.V., Lyadov V., Fu W., Mi W., Jeong W.K., Leclercq W.K.G., De Sousa X., Zhao X., Li X., Wang X., Yang X., Zhang X., Dong Y., Erushevich Y., Takii Y., Sumi Y., Loli Y.T., Yifat Y.L., Shimada Y., Nabeya Y., Ide Y., Wu Y., Tsukada Y., Miyamoto Y., Toiyama Y., Fujie Y., Kaneko Y., Mokutani Y., Fujii Y., Kanemitsu Y., Medkova Y., Chen Y., Ruiz Y.G., Kinugasa Y., Sow Z., Razzaq Z., Wang Z., Liu Z., Han Z., Tai Z., Lai Z., Ng Z.Q., Dambrauskas Z., ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), Center of Experimental and Molecular Medicine, Graduate School, ACS - Pulmonary hypertension & thrombosis, AII - Infectious diseases, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Paediatric Surgery, ARD - Amsterdam Reproduction and Development, An, Y., Bellato, V., Konishi, T., Pellino, G., Sensi, B., Siragusa, L., Franceschilli, M., Sica, G. S., Kefleyesus, A., Hoofwijk, A. G. M., Eldaly, A. S., Gonzalez, A., Jawad, A., Jooma, A., Hafez, A. M., Rubio, A. V., Landaluce-Olavarria, A., Wu, A., Nagatsu, A., Inoue, A., Kanamoto, A., Ouchi, A., El-Hussuna, A., Vazquez-Melero, A., Wolthuis, A. M., Peral, A. M., Lozano, A. C., Efremov, A., Ryasantsev, A. V., Di Giorgio, A., Parente, A., Tamburrini, A., Alo, A., Forero-Torres, A., Vahrmeijer, A. L., Varabei, A., Hinojosa, S., Balkan, A. Z. A., Frontali, A., Oleg, A., Soler-Silva, A., Makni, A., Andre, A., Cabrera, A. M. G., Fernandez, A. M. G., Minaya-Bravo, A. M., Rodriguez-Sanchez, A., Musina, A. -M., Pangeni, A., Zolotko, A., Tonoyan, A., Balla, A., Belli, A., Cavallaro, A., Chierici, A., Divizia, A., Bucci, A. F., Salido, A. J., Morini, A., Muratore, A., Vignali, A., Chitul, A., Sebastian, D. A., Pcolkins, A., Shchegolev, A., Hollenbeck, A., Wisneski, A., Iossa, A., D'Amore, A., Hunter, A., Hesketh, A. J., La Brocca, A., Spinelli, A., Caires, A., D'Alessandro, A., Correo, A. F. S. L., Macri, A., Navarro-Sanchez, A., Pronk, A., Akunc, A., Mehri, A., Pelta, A., Papadopoulos, A., Kechagias, A., Rashid, A., Ramazanov, A., Chandio, A., Kohyama, A., Nishimura, A., Ohkawa, A., Dulskas, A., Jamal, A., Mariani, A., Unal, A. G., Karagoz, A., Ozkan, B. B., Salih, B., Gulcu, B., Pessia, B., Martin-Perez, B., Ielpo, B., Tulelli, B., Yang, B., Mhamed, B., Murphy, B., Pirozzi, B. M., Langenhoff, B., Belevi, B., Guney, B., Ng, C., Rueda, C., Roxburgh, C. S., Feo, C. V., Ferrari, C., Gazia, C., Pratesi, C., Ratto, C., Santacruz, C. C., Arroyave, C. R. M., Macias, C., Fernandez, C. G., Fernandez, C. C., Curtis-Martinez, C., Fortmann, C., Kim, C., Galeano, C. U., Barroso, C., Baldi, C., Foppa, C., Formisano, C., Li, C., Ding, C., Wang, C., Iacusso, C., Yang, C., Pizzera, C., Skias, C., Chouliras, C., Liakos, C., Matsuda, C., Wu, C. -Y., Ozaslan, C., Tanda, C., Tommaso, C. M., Dagorno, C., Ramos, C. P. A., Arcudi, C., Coco, C., Morales, C. M., Ali, M. Z., Lozano, C. C., Sala, C., Leo, C. A., Scarpa, C. R., Ferro, C. V., Fernandez, C. M., Morales-Garcia, D., Nakano, D., Cristian, D., Hechtl, D., Canovas, D. T., Calabrese, D., Rega, D., Ferraro, D., Morezzi, D., Sommacale, D., Brogden, D., Miskovic, D., Merlini, D., Pertile, D., Coniglio, D., Zhu, D., Wu, D., Coletta, D., Rubio, D. R., Sasia, D., Fillipov, D., Russiello, D., Dardanov, D., Consten, E. C. J., Smolskas, E., Muttillo, E. M., Jones, E., Sunami, E., Etienne, E. -H., Chalkiadaki, E., Giacomelli, E., Karbovnichaya, E., Ruiz-Ucar, E., Guaitoli, E., Samadov, E., Jovine, E., Treppiedi, E., Vaterlini, E. M., Zambaiti, E., Moggia, E., Coetzee, E., Chisari, E., D'Errico, E., Ciofic, E., Pena, E., Kurt, E., Balik, E., Gunay, E., Sivrikoz, E., Andolfi, E., Araimo, E., Lucci, E., Opocher, E., Pinotti, E., Rubino, E., Reyhan, E., Mazzotta, E., Navarro, E. B., El-Helou, E., Licardie-Bolanos, E., Porto, E. I., Contreras, E., Boerma, E. -J., Cianchi, F., Marino, F., Uggeri, F., Han, F., Calculli, F., Falaschi, F., Ghignone, F., Perrone, F., Borghi, F., Garcia, F., Agresta, F., Cananzi, F. C. M., Mendoza-Moreno, F., Cengiz, F., Almeida, F. M., Baracchi, F., Carannante, F., La Torre, F., Fernandes, F., Friedmacher, F., Grama, F., Carissimi, F., Pecchini, F., Bianco, F., Colombo, F., Ferrara, F., Litta, F., Carrano, F. M., Martignoni, F., Tasselli, F. M., Milone, F., Pata, F., Sammartino, F., Zambianchi, F., Barragan, F., Herrero, F., Schlottmann, F., Den Boer, F. C., Pfeffer, F., Fujita, F., Navarra, G., Herrera-Almario, G., Pozzo, G., Capolupo, G. T., Van Ramshorst, G. H., Liscia, G., Gallo, G., Asawa, G., Wang, G., Raiyani, G., Beets, G., Naval, G. S., Jin, G., Chang, G. J., Saakian, G., Kahane, G., Borroni, G., Secco, G. L., Baiocchi, G. L., Baronio, G., Pagano, G., Pattacini, G. C., Lisi, G., Milito, G., Sinibaldi, G., Serrao, G., Bagaglini, G., Sarro, G., Brisinda, G., Candilio, G., Mangiameli, G., Giuliani, G., Martin-Martin, G. P., Bodzin, G., Leon, G., Mackay, G., Vasil, G., Palmisano, G., Giovanna, G. M., Fernandez, G. C., Steingel, G. B., Zhang, G., Choi, G. S., Chen, H., Hirose, H., Kayano, H., Ulgur, H. S., Impellizzeri, H., Ariola, H., Liu, H., Medina, H., Miyauchi, H., Takahashi, H., Hayashi, H., Ishikawa, H., Ishida, H., De Vries, H., Ulman, H., Kon, H., Ota, H., Akamatsu, H., Tamagawa, H., Shoji, H., Egi, H., Matsubara, H., Miki, H., Elfeki, H., Lin, H. -H., Giani, I., Caravaca-Garcia, I., Takemasa, I., Angriman, I., Negoi, I., Volkova, I., Russo, I., Kronberger, I. E., Shageev, I., Aydin, I., Mora Guzman, I., Novak, I., Giuliano, I., Rachmuth, J., Ngu, J. C. -Y., Glasbey, J., Stoot, J., Zatecky, J., Melenhorst, J., Van Der Wal, J. B. C., Leijtens, J., Bogach, J., Elliott, J., De Wilt, J. H. W., Han, J., Cui, J., Liu, J., Khan, J., Wirawan, J. P., Zhang, J., Manyari, J. D. O., Doerner, J., Bock, J., Konsten, J., Castro, J. M., Grobas, J. P., Pereira, J., Juloski, J., Laina, J. L. B., Solorzano, J. J., Lopez, J. R. G., Li, J., Watanabe, J., Kwak, J. -M., Hasegawa, J., Hiro, J., Sergey, K., Zhang, K., Nagahori, K., Martinez, K., Tokuhara, K., Danno, K., Uehara, K., Yoshimatsu, K., Ehara, K., Ueda, K., Suda, K., Yamamoto, K., Ishimaru, K., Kimura, K., Hirata, K., Deen, K., Imaizumi, K., Yamada, J., Tanakura, K., Rida, K., Sugimoto, K., Kotaro, K., Shi, K., Okabayashi, K., Hida, K., Kataoka, K., Hongo, K., Xia, K., Tseng, L., Reime, L., Lorenzon, L., Ruano, L. M., Zhou, L., De Nes, L., Brandariz, L., Morini, L., Petagna, L., Ripamonti, L., Martinez, L. H., Pio, L., Sacco, L., Carvalho, L., Zorcolo, L., Perez-Sanchez, L. E., Esparza, L. H. R., Aguilar, L. T., Garner, M., Sugimoto, M., Nagashima, M., Shiozawa, M., Simone, M., Ferrer-Marquez, M., Carvalho, M., Alifano, M., Arganini, M., Calussi, M., Catarci, M., Allaix, M. E., Forlin, M., Milone, M., Paci, M., Fodor, M., Antipova, M., Martos, M. B., Giuffrida, M. C., Tabernilla, M. D., Quiros, M. J. A., Lemma, M., Correo, M. L. R. D., Malowiecka, M., Bellomo, M. P., Fernandez, M. R., Socias, M., Rizk, M., Aurora, M., Antolinez, M. A., Ninkovic, M., Giuffrida, M., De Roos, M. A. J., Lara, M. C., Agustin, M. C., Cuadrado, M., Pascual, M., Lemmerer, M., Carlos, R., Okamoto, M., Miyo, M., Inomata, M., Ikenaga, M., Tsujie, M., Yasuno, M., Kotake, M., Sato, M., Yasui, M., Lavazza, M., Rottoli, M., Zuin, M., Zuluaga, M., Cervellera, M., Cesari, M., Zizzo, M., Garino, M., Ghirardi, M., Montuori, M., Podda, M., Santarelli, M., Koc, M. A., Baini, M., Campanelli, M., Manigrasso, M., Zuolo, M., Cunha, M. F., Misca, M., Slavchev, M., Danilov, M., Shigaev, M., Martens, M., Kobayashi, M., Ren, M., Ishizuka, M., Hassan, M. M., Siblini, M., Sahloul, M., Keramati, M. R., Karunakaran, M., Markel, M., Majeed, M., Younis, M. U., Akin, M. I., Laraibe, M., Derebey, M., Kendirci, M., Fukunaga, M., Matsubara, N., Ordaz, N. E. C., Samalavicius, N. E., Keeratibharat, N., de Angelis, N., Gica, N., Mariani, N. M., Ramino, N., Falco, N., Smart, N., De Korte, N., Kok, N. F. M., Jamieson, N. B., Aberyasev, N., Bruklich, N., Ichikawa, N., Miyoshi, N., De Palma, N., Figueiredo, N., Torrecilla, N. O., Dybov, O. G., Yudin, O., Crepin, O., Gomez, O., Sert, O. Z., Lominchar, P. L., Menendez, P., De Nardi, P., Tejedor, P., Jordan, P., Tan, P., Marsanic, P., Natalya, P., Banos, P. P., Rebasa, P., Neary, P. M., Tanis, P., Giustacchini, P., Anoldo, P., Concejo, P., Cao, P., Chandrasinghe, P., Abeyratne, P., Wang, Q., Klicks, R. J., Riquelme, R. F., Galli, R., Gianesini, R., Moorjani, R. G., Deshpande, R. K., Gorter, R., Ledesma, R. L., Ruslan, R., Chhabra, R., Talreja-Pelaez, R., Suzuki, R., Balestri, R., Rosati, R., Kiblawi, R., Martins, R., Angelico, R., Tutino, R., Persiani, R., Pollastri, R., Lopez, R. G., Perez, R. O., Hompes, R., Lukanin, R., Roser Termes Serra, R., Brunaccino, R., Nakanishi, R., Stefan, S., Hernandez, S. P. S., Di Carlo, S., Ingallinella, S., Domoto, S., Ikeda, S., Mikalauskas, S., Kim, S. H., Mantova, S., Barbuta, S., Li, S., Yamaguchi, S., Yamagishi, S., Homma, S., Tsujinaka, S., Yoshioka, S., Mori, S., Tewari, S., Rayman, S., Horiuchi, S., Matoba, S., Morita, S., Yaman, S., Vigna, S., Testa, S., Ng, S., Deidda, S., Cicconi, S., Di Maria, S., Sibio, S., Ersoz, S., Pejkova, S., Altarifi, S., He, S., Malakorn, S., Meindert, S., Sumikawa, S., Parmar, S., Uranitsch, S., D'Ugo, S., Giuliani, S., Breukink, S., Lee, S. -H., Hata, T., Ishikawa, T., Akiyoshi, T., Azuma, T., Kobatake, T., Fukuzaki, T., Aiyama, T., Yamada, T., Garmanova, T., Gomez-Sanchez, T., Yamaguchi, T., Flores, T. D. J., Usub, T., Tsuruma, T., Shimizu, T., Hristov, T. G., Van Loon, T., Funakoshi, T., Manzia, T. M., Kiyomatsu, T., Katayama, T., Kazuhito, U., Elmore, U., Grossi, U., Truchalev, V. A., Rodriguez, V. S., Testa, V., Tonini, V., Celentano, V., Bettencourt, V., Mammadov, V., Leyva, V. A. G., Mariscal, V. G. O., Seid, V. E., Klemann, V., Turrado-Rodriguez, V., Papagni, V., Vento, V., Frering, V., Vigorita, V., Petrove, V. V., Lyadov, V., Fu, W., Mi, W., Jeong, W. K., Leclercq, W. K. G., De Sousa, X., Zhao, X., Li, X., Wang, X., Yang, X., Zhang, X., Dong, Y., Erushevich, Y., Takii, Y., Sumi, Y., Loli, Y. T., Yifat, Y. L., Shimada, Y., Nabeya, Y., Ide, Y., Wu, Y., Tsukada, Y., Miyamoto, Y., Toiyama, Y., Fujie, Y., Kaneko, Y., Mokutani, Y., Fujii, Y., Kanemitsu, Y., Medkova, Y., Chen, Y., Ruiz, Y. G., Kinugasa, Y., Sow, Z., Razzaq, Z., Wang, Z., Liu, Z., Han, Z., Tai, Z., Lai, Z., Ng, Z. Q., Dambrauskas, Z., An, Y, Bellato, V, Konishi, T, Pellino, G, Sensi, B, Siragusa, L, Franceschilli, M, Sica, G, Kefleyesus, A, Hoofwijk, A, Eldaly, A, Gonzalez, A, Jawad, A, Jooma, A, Hafez, A, Rubio, A, Landaluce-Olavarria, A, Wu, A, Nagatsu, A, Inoue, A, Kanamoto, A, Ouchi, A, El-Hussuna, A, Vazquez-Melero, A, Wolthuis, A, Peral, A, Lozano, A, Efremov, A, Ryasantsev, A, Di Giorgio, A, Parente, A, Tamburrini, A, Alo, A, Forero-Torres, A, Vahrmeijer, A, Varabei, A, Hinojosa, S, Balkan, A, Frontali, A, Oleg, A, Soler-Silva, A, Makni, A, Andre, A, Cabrera, A, Fernandez, A, Minaya-Bravo, A, Rodriguez-Sanchez, A, Musina, A, Pangeni, A, Zolotko, A, Tonoyan, A, Balla, A, Belli, A, Cavallaro, A, Chierici, A, Divizia, A, Bucci, A, Salido, A, Morini, A, Muratore, A, Vignali, A, Chitul, A, Sebastian, D, Pcolkins, A, Shchegolev, A, Hollenbeck, A, Wisneski, A, Iossa, A, D'Amore, A, Hunter, A, Hesketh, A, La Brocca, A, Spinelli, A, Caires, A, D'Alessandro, A, Correo, A, Macri, A, Navarro-Sanchez, A, Pronk, A, Akunc, A, Mehri, A, Pelta, A, Papadopoulos, A, Kechagias, A, Rashid, A, Ramazanov, A, Chandio, A, Kohyama, A, Nishimura, A, Ohkawa, A, Dulskas, A, Jamal, A, Mariani, A, Unal, A, Karagoz, A, Ozkan, B, Salih, B, Gulcu, B, Pessia, B, Martin-Perez, B, Ielpo, B, Tulelli, B, Yang, B, Mhamed, B, Murphy, B, Pirozzi, B, Langenhoff, B, Belevi, B, Guney, B, Ng, C, Rueda, C, Roxburgh, C, Feo, C, Ferrari, C, Gazia, C, Pratesi, C, Ratto, C, Santacruz, C, Arroyave, C, Macias, C, Fernandez, C, Curtis-Martinez, C, Fortmann, C, Kim, C, Galeano, C, Barroso, C, Baldi, C, Foppa, C, Formisano, C, Li, C, Ding, C, Wang, C, Iacusso, C, Yang, C, Pizzera, C, Skias, C, Chouliras, C, Liakos, C, Matsuda, C, Wu, C, Ozaslan, C, Tanda, C, Tommaso, C, Dagorno, C, Ramos, C, Arcudi, C, Coco, C, Morales, C, Ali, M, Lozano, C, Sala, C, Leo, C, Scarpa, C, Ferro, C, Morales-Garcia, D, Nakano, D, Cristian, D, Hechtl, D, Canovas, D, Calabrese, D, Rega, D, Ferraro, D, Morezzi, D, Sommacale, D, Brogden, D, Miskovic, D, Merlini, D, Pertile, D, Coniglio, D, Zhu, D, Wu, D, Coletta, D, Rubio, D, Sasia, D, Fillipov, D, Russiello, D, Dardanov, D, Consten, E, Smolskas, E, Muttillo, E, Jones, E, Sunami, E, Etienne, E, Chalkiadaki, E, Giacomelli, E, Karbovnichaya, E, Ruiz-Ucar, E, Guaitoli, E, Samadov, E, Jovine, E, Treppiedi, E, Vaterlini, E, Zambaiti, E, Moggia, E, Coetzee, E, Chisari, E, D'Errico, E, Ciofic, E, Pena, E, Kurt, E, Balik, E, Gunay, E, Sivrikoz, E, Andolfi, E, Araimo, E, Lucci, E, Opocher, E, Pinotti, E, Rubino, E, Reyhan, E, Mazzotta, E, Navarro, E, El-Helou, E, Licardie-Bolanos, E, Porto, E, Contreras, E, Boerma, E, Cianchi, F, Marino, F, Uggeri, F, Han, F, Calculli, F, Falaschi, F, Ghignone, F, Perrone, F, Borghi, F, Garcia, F, Agresta, F, Cananzi, F, Mendoza-Moreno, F, Cengiz, F, Almeida, F, Baracchi, F, Carannante, F, La Torre, F, Fernandes, F, Friedmacher, F, Grama, F, Carissimi, F, Pecchini, F, Bianco, F, Colombo, F, Ferrara, F, Litta, F, Carrano, F, Martignoni, F, Tasselli, F, Milone, F, Pata, F, Sammartino, F, Zambianchi, F, Barragan, F, Herrero, F, Schlottmann, F, Den Boer, F, Pfeffer, F, Fujita, F, Navarra, G, Herrera-Almario, G, Pozzo, G, Capolupo, G, Van Ramshorst, G, Liscia, G, Gallo, G, Asawa, G, Wang, G, Raiyani, G, Beets, G, Naval, G, Jin, G, Chang, G, Saakian, G, Kahane, G, Borroni, G, Secco, G, Baiocchi, G, Baronio, G, Pagano, G, Pattacini, G, Lisi, G, Milito, G, Sinibaldi, G, Serrao, G, Bagaglini, G, Sarro, G, Brisinda, G, Candilio, G, Mangiameli, G, Giuliani, G, Martin-Martin, G, Bodzin, G, Leon, G, Mackay, G, Vasil, G, Palmisano, G, Giovanna, G, Fernandez, G, Steingel, G, Zhang, G, Choi, G, Chen, H, Hirose, H, Kayano, H, Ulgur, H, Impellizzeri, H, Ariola, H, Liu, H, Medina, H, Miyauchi, H, Takahashi, H, Hayashi, H, Ishikawa, H, Ishida, H, De Vries, H, Ulman, H, Kon, H, Ota, H, Akamatsu, H, Tamagawa, H, Shoji, H, Egi, H, Matsubara, H, Miki, H, Elfeki, H, Lin, H, Giani, I, Caravaca-Garcia, I, Takemasa, I, Angriman, I, Negoi, I, Volkova, I, Russo, I, Kronberger, I, Shageev, I, Aydin, I, Mora Guzman, I, Novak, I, Giuliano, I, Rachmuth, J, Ngu, J, Glasbey, J, Stoot, J, Zatecky, J, Melenhorst, J, Van Der Wal, J, Leijtens, J, Bogach, J, Elliott, J, De Wilt, J, Han, J, Cui, J, Liu, J, Khan, J, Wirawan, J, Zhang, J, Manyari, J, Doerner, J, Bock, J, Konsten, J, Castro, J, Grobas, J, Pereira, J, Juloski, J, Laina, J, Solorzano, J, Lopez, J, Li, J, Watanabe, J, Kwak, J, Hasegawa, J, Hiro, J, Sergey, K, Zhang, K, Nagahori, K, Martinez, K, Tokuhara, K, Danno, K, Uehara, K, Yoshimatsu, K, Ehara, K, Ueda, K, Suda, K, Yamamoto, K, Ishimaru, K, Kimura, K, Hirata, K, Deen, K, Imaizumi, K, Yamada, J, Tanakura, K, Rida, K, Sugimoto, K, Kotaro, K, Shi, K, Okabayashi, K, Hida, K, Kataoka, K, Hongo, K, Xia, K, Tseng, L, Reime, L, Lorenzon, L, Ruano, L, Zhou, L, De Nes, L, Brandariz, L, Morini, L, Petagna, L, Ripamonti, L, Martinez, L, Pio, L, Sacco, L, Carvalho, L, Zorcolo, L, Perez-Sanchez, L, Esparza, L, Aguilar, L, Garner, M, Sugimoto, M, Nagashima, M, Shiozawa, M, Simone, M, Ferrer-Marquez, M, Carvalho, M, Alifano, M, Arganini, M, Calussi, M, Catarci, M, Allaix, M, Forlin, M, Milone, M, Paci, M, Fodor, M, Antipova, M, Martos, M, Giuffrida, M, Tabernilla, M, Quiros, M, Lemma, M, Correo, M, Malowiecka, M, Bellomo, M, Fernandez, M, Socias, M, Rizk, M, Aurora, M, Antolinez, M, Ninkovic, M, De Roos, M, Lara, M, Agustin, M, Cuadrado, M, Pascual, M, Lemmerer, M, Carlos, R, Okamoto, M, Miyo, M, Inomata, M, Ikenaga, M, Tsujie, M, Yasuno, M, Kotake, M, Sato, M, Yasui, M, Lavazza, M, Rottoli, M, Zuin, M, Zuluaga, M, Cervellera, M, Cesari, M, Zizzo, M, Garino, M, Ghirardi, M, Montuori, M, Podda, M, Santarelli, M, Koc, M, Baini, M, Campanelli, M, Manigrasso, M, Zuolo, M, Cunha, M, Misca, M, Slavchev, M, Danilov, M, Shigaev, M, Martens, M, Kobayashi, M, Ren, M, Ishizuka, M, Hassan, M, Siblini, M, Sahloul, M, Keramati, M, Karunakaran, M, Markel, M, Majeed, M, Younis, M, Akin, M, Laraibe, M, Derebey, M, Kendirci, M, Fukunaga, M, Matsubara, N, Ordaz, N, Samalavicius, N, Keeratibharat, N, de Angelis, N, Gica, N, Mariani, N, Ramino, N, Falco, N, Smart, N, De Korte, N, Kok, N, Jamieson, N, Aberyasev, N, Bruklich, N, Ichikawa, N, Miyoshi, N, De Palma, N, Figueiredo, N, Torrecilla, N, Dybov, O, Yudin, O, Crepin, O, Gomez, O, Sert, O, Lominchar, P, Menendez, P, De Nardi, P, Tejedor, P, Jordan, P, Tan, P, Marsanic, P, Natalya, P, Banos, P, Rebasa, P, Neary, P, Tanis, P, Giustacchini, P, Anoldo, P, Concejo, P, Cao, P, Chandrasinghe, P, Abeyratne, P, Wang, Q, Klicks, R, Riquelme, R, Galli, R, Gianesini, R, Moorjani, R, Deshpande, R, Gorter, R, Ledesma, R, Ruslan, R, Chhabra, R, Talreja-Pelaez, R, Suzuki, R, Balestri, R, Rosati, R, Kiblawi, R, Martins, R, Angelico, R, Tutino, R, Persiani, R, Pollastri, R, Lopez, R, Perez, R, Hompes, R, Lukanin, R, Roser Termes Serra, R, Brunaccino, R, Nakanishi, R, Stefan, S, Hernandez, S, Di Carlo, S, Ingallinella, S, Domoto, S, Ikeda, S, Mikalauskas, S, Kim, S, Mantova, S, Barbuta, S, Li, S, Yamaguchi, S, Yamagishi, S, Homma, S, Tsujinaka, S, Yoshioka, S, Mori, S, Tewari, S, Rayman, S, Horiuchi, S, Matoba, S, Morita, S, Yaman, S, Vigna, S, Testa, S, Ng, S, Deidda, S, Cicconi, S, Di Maria, S, Sibio, S, Ersoz, S, Pejkova, S, Altarifi, S, He, S, Malakorn, S, Meindert, S, Sumikawa, S, Parmar, S, Uranitsch, S, D'Ugo, S, Giuliani, S, Breukink, S, Lee, S, Hata, T, Ishikawa, T, Akiyoshi, T, Azuma, T, Kobatake, T, Fukuzaki, T, Aiyama, T, Yamada, T, Garmanova, T, Gomez-Sanchez, T, Yamaguchi, T, Flores, T, Usub, T, Tsuruma, T, Shimizu, T, Hristov, T, Van Loon, T, Funakoshi, T, Manzia, T, Kiyomatsu, T, Katayama, T, Kazuhito, U, Elmore, U, Grossi, U, Truchalev, V, Rodriguez, V, Testa, V, Tonini, V, Celentano, V, Bettencourt, V, Mammadov, V, Leyva, V, Mariscal, V, Seid, V, Klemann, V, Turrado-Rodriguez, V, Papagni, V, Vento, V, Frering, V, Vigorita, V, Petrove, V, Lyadov, V, Fu, W, Mi, W, Jeong, W, Leclercq, W, De Sousa, X, Zhao, X, Li, X, Wang, X, Yang, X, Zhang, X, Dong, Y, Erushevich, Y, Takii, Y, Sumi, Y, Loli, Y, Yifat, Y, Shimada, Y, Nabeya, Y, Ide, Y, Wu, Y, Tsukada, Y, Miyamoto, Y, Toiyama, Y, Fujie, Y, Kaneko, Y, Mokutani, Y, Fujii, Y, Kanemitsu, Y, Medkova, Y, Chen, Y, Ruiz, Y, Kinugasa, Y, Sow, Z, Razzaq, Z, Wang, Z, Liu, Z, Han, Z, Tai, Z, Lai, Z, Ng, Z, and Dambrauskas, Z

Subjects
Surgery, COVID-19, medicine.medical_specialty, 2019-20 coronavirus outbreak, Infectious Disease Transmission, Patient-to-Professional, survey, covid19, Coronavirus disease 2019 (COVID-19), Attitude of Health Personnel, Settore MED/18 - CHIRURGIA GENERALE, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Infectious Disease Transmission, COVID-19. Global surgery, MEDLINE, Global Health, NO, Patient-to-Professional, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Surveys and Questionnaires, Correspondence, medicine, Global health, Infection control, Humans, General, Personal protective equipment, Personal Protective Equipment, LS7_4, Surgeons, Infection Control, covid-19, pandemic, surgery, SARS-CoV-2, business.industry, Vaccination, COVID-19, covid, Fear, Settore MED/18, Occupational Diseases, Surgeon - infection - COVID19 - survey, Family medicine, Surgery, business
Abstract

During the last three months, COVID- 19 pandemic had led to a serious backlog of operations globally, and plans for restarting operation are imperative. Recommendations for surgical activities were studied, aiming to protect the surgical staff from being infected. In the meantime, it is also important to give attention to the surgeon’s personal feeling during work. We conducted a survey to investigate global surgi- cal practices during the COVID-19 pandemic, and the surgeon’s personal feeling was also investigated in the sur- vey. In this special letter, we performed multivariate analysis to explore factors that associated with surgeon’s fear of getting infected by COVID-19.

Published
2020

15. Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis

Author

Apostolos Tsapas, David R. Matthews, Thomas Karagiannis, Eleni Bekiari, Aris Liakos, Theodoros Michailidis, and Ioannis Avgerinos

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, Internal medicine, Internal Medicine, medicine, Empagliflozin, Humans, Hypoglycemic Agents, Adverse effect, Liraglutide, business.industry, Semaglutide, medicine.disease, Blood pressure, Diabetes Mellitus, Type 2, business, medicine.drug
Abstract

Aim To assess the efficacy and safety of oral semaglutide, a novel glucagon-like peptide-1 receptor agonist, for patients with type 2 diabetes. Methods We searched Medline, Embase, the Cochrane Library and grey literature sources up to July 1, 2019 for randomized controlled trials (RCTs) comparing oral semaglutide with placebo or other antidiabetic agents. The primary outcome was change from baseline in HbA1c. Secondary outcomes included change from baseline in body weight and blood pressure, cardiovascular endpoints, severe hypoglycaemia, gastrointestinal adverse events and diabetic retinopathy. We synthesized results using weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, along with 95% confidence intervals (CIs). Results We included 11 RCTs with 9890 patients in the systematic review. Compared with placebo, oral semaglutide reduced HbA1c and body weight (WMD -0.89%, 95% CI -1.07 to -0.71 and - 2.99 kg, 95% CI -3.69 to -2.30, respectively). Oral semaglutide was also superior to other active comparators (including liraglutide, empagliflozin and sitaglipitin) in terms of lowering HbA1c (WMD -0.35%, 95% CI -0.43 to -0.26) and reduction of body weight (WMD -1.48 kg, 95% CI -2.28 to -0.67), and had a favourable effect on systolic blood pressure. Compared with placebo, oral semaglutide reduced all-cause mortality (OR 0.58, 95% CI 0.37 to 0.92) and cardiovascular mortality (OR 0.55, 95% CI 0.31 to 0.98), and had a neutral effect on myocardial infarction, stroke, severe hypoglycaemia and diabetic retinopathy. However, treatment with oral semaglutide increased the incidence of nausea, vomiting and diarrhea, while events of acute pancreatitis were rare. Conclusions Oral semaglutide can effectively and safely reduce blood glucose, body weight and systolic blood pressure. Nevertheless, it is associated with increased incidence of gastrointestinal adverse events. Further research is needed to clarify its long-term safety and comparative effectiveness against other antidiabetic agents.

Published
2019
Full Text
View/download PDF

16. Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis

Author

Isaac H. Solomon, Kaelyn C. Cummins, Sarah P. Hammond, Amanda E Kusztos, Francisco M. Marty, Matthew P. Cheng, Tyler D. Bold, Alisha Pandit, Esther Arbona-Haddad, Kaiwen Chen, Sophia Koo, José Luis Orejas, and Alexis Liakos

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, Posaconazole, Antifungal Agents, Pyridines, 030106 microbiology, Dermatology, Aspergillosis, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Nitriles, medicine, Humans, Clinical efficacy, Adverse effect, Aged, Aged, 80 and over, Voriconazole, Adult patients, business.industry, General Medicine, Middle Aged, Triazoles, medicine.disease, Treatment Outcome, Infectious Diseases, Female, business, Invasive Fungal Infections, Cohort study, medicine.drug
Abstract

In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Published
2019
Full Text
View/download PDF

17. 17‐β estradiol attenuates the pro‐oxidant activity of corticotropin‐releasing hormone in macroendothelial cells

Author

Panagiotis Liakos, Maria Filiponi, Christina Befani, Αlexandra Bargiota, Sofia Gougoura, and George N. Koukoulis

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.drug_class, medicine.disease_cause, Nitric oxide, Superoxide dismutase, 03 medical and health sciences, Corticotropin-releasing hormone, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, chemistry.chemical_classification, Reactive oxygen species, biology, Chemistry, Cell Biology, General Medicine, Glutathione, Endothelial stem cell, 030104 developmental biology, Endocrinology, Estrogen, 030220 oncology & carcinogenesis, biology.protein, hormones, hormone substitutes, and hormone antagonists, Oxidative stress
Abstract

Corticotropin-releasing hormone, which is the predominant regulator of neuroendocrine responses to stress, attenuates inflammation through stimulation of glucocorticoid release. Enhanced corticotropin-releasing hormone expression has been detected in inflammatory cells of the vascular endothelium, where it acts as a local regulator of endothelial redox homeostasis. Estrogens have beneficial effects on endothelial integrity and function, though the mechanism underlying their antioxidative effect remains as yet largely unknown. We therefore investigated the effect of 17β-estradiol on pro-oxidant action of corticotropin-releasing hormone in vitro in macroendothelial cells, and, more specifically, the role of 17β-estradiol on corticotropin-releasing hormone-induced activities/release of the antioxidant enzymes namely, endothelial nitric oxide synthase, superoxide dismutase, catalase, and glutathione. We observed that 17β-estradiol abolished the stimulatory effect of corticotropin-releasing hormone on intracellular reactive oxygen species levels and counteracted its inhibitory effect on endothelial nitric oxide synthase activity and nitric oxide release. In addition, 17β-estradiol significantly induced superoxide dismutase and catalase activity, an effect that was not significantly influenced by corticotropin-releasing hormone. Finally, 17β-estradiol significantly increased glutathione levels and the glutathione/glutathione + glutathione disulfide ratio, an action that was partially blocked by corticotropin-releasing hormone. Our results reveal that 17β-estradiol counterbalances corticotropin-releasing hormone-mediated pro-inflammatory action and thereby maintains the physiological threshold of the endothelial cell redox environment. These observations may be of importance, considering the protective role of estrogen in the development of atherosclerosis.

Published
2019
Full Text
View/download PDF

20. Author response for 'Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis'

Author

null Tsapas, Apostolos, null Karagiannis, Thomas, null Kakotrichi, Panagiota, null Avgerinos, Ioannis, null Mantsiou, Chrysanthi, null Tousinas, Georgios, null Manolopoulos, Apostolos, null Liakos, Aris, null Malandris, Konstantinos, null Matthews, David R., and null Bekiari, Eleni

Published
2021
Full Text
View/download PDF

21. Author response for 'Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis'

Author

Apostolos Tsapas, Konstantinos Malandris, David R. Matthews, Tom C. Karagiannis, Georgios Tousinas, Chrysanthi Mantsiou, Apostolos Manolopoulos, Eleni Bekiari, Ioannis Avgerinos, Aris Liakos, and Panagiota Kakotrichi

Subjects
Glucose lowering, medicine.medical_specialty, Blood pressure, business.industry, Meta-analysis, Internal medicine, medicine, In patient, Type 2 diabetes, medicine.disease, Body weight, business
Published
2021
Full Text
View/download PDF

24. Author response for 'Glucagon‐like peptide 1 receptor agonists and sodium glucose co‐transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta‐analysis'

Author

Konstantinos Malandris, Panagiota Kakotrichi, Apostolos Tsapas, Chrysanthi Mantsiou, Eleni Bekiari, Tom C. Karagiannis, Aris Liakos, and Ioannis Avgerinos

Subjects
Combination therapy, business.industry, Sodium, chemistry.chemical_element, Transporter, Type 2 diabetes, Pharmacology, medicine.disease, Glucagon-like peptide-1, chemistry, Meta-analysis, medicine, Receptor, business
Published
2020
Full Text
View/download PDF

25. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial

Author

Iakovos Avramidis, Nikolaos Tentolouris, George Dimitriadis, Kalliopi Kotsa, Panagiota Boura, Vaia Lambadiari, Spyridon Gerou, Apostolos Tsapas, Aris Liakos, Konstantinos Kitsios, and Alexandra Bargiota

Subjects
Blood Glucose, Male, Ambulatory blood pressure, Endocrinology, Diabetes and Metabolism, Placebo-controlled study, Blood Pressure, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Placebos, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Double-Blind Method, Heart Rate, Internal Medicine, medicine, Humans, Aged, business.industry, Liraglutide, Blood Pressure Monitoring, Ambulatory, Middle Aged, medicine.disease, Lipids, Blood pressure, Diabetes Mellitus, Type 2, Anesthesia, Hypertension, Ambulatory, Female, business, Pioglitazone, medicine.drug
Abstract

Aims To assess the effect of liraglutide on 24-hour ambulatory blood pressure and heart rate in patients with hypertension (pre- and stage 1 hypertension) and inadequately controlled Type 2 diabetes (glycated haemoglobin 7%-10% [53-86 mmol/mol]). Materials and methods Eligible patients for this investigator-initiated, parallel-group, randomized, double-blind trial were on stable background antihyperglycaemic therapy excluding insulin, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors. Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks. The primary outcome was change in 24-hour ambulatory systolic blood pressure (SBP), and secondary outcomes included change in ambulatory diastolic blood pressure (DBP) and heart rate. We also assessed renal sodium handling. Results Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31). All participants received background therapy with metformin, whilst 35.5% were treated concomitantly with sulphonylureas and 14.5% with pioglitazone. Compared with placebo, liraglutide reduced 24-hour SBP by -5.73 mm Hg (95% confidence interval [CI] -9.81 to -1.65) and had a neutral effect on 24-hour DBP (mean difference - 1.42 mm Hg; 95% CI -4.25 to 1.40), whilst increasing 24-hour heart rate by 6.16 beats/min (95% CI 3.25 to 9.07). Findings were consistent for daytime and night-time measurements. Liraglutide did not increase urine sodium excretion. Conclusion Based on 24-hour ambulatory measurements, short-term treatment with liraglutide had a favourable effect on SBP whilst increasing heart rate.

Published
2018
Full Text
View/download PDF

27. Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis

Author

Tsapas, Apostolos, primary, Karagiannis, Thomas, additional, Kakotrichi, Panagiota, additional, Avgerinos, Ioannis, additional, Mantsiou, Chrysanthi, additional, Tousinas, Georgios, additional, Manolopoulos, Apostolos, additional, Liakos, Aris, additional, Malandris, Konstantinos, additional, Matthews, David R., additional, and Bekiari, Eleni, additional

Published
2021
Full Text
View/download PDF

28. Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta‐analysis

Author

Avgerinos, Ioannis, primary, Manolopoulos, Apostolos, additional, Michailidis, Theodoros, additional, Kitsios, Konstantinos, additional, Liakos, Aris, additional, Karagiannis, Thomas, additional, Dimitrakopoulos, Konstantinos, additional, Matthews, David R., additional, Tsapas, Apostolos, additional, and Bekiari, Eleni, additional

Published
2021
Full Text
View/download PDF

32. Hypoxia upregulates integrin gene expression in microvascular endothelial cells and promotes their migration and capillary-like tube formation

Author

Christina Befani and Panagiotis Liakos

Subjects
0301 basic medicine, Tube formation, Gene knockdown, biology, Angiogenesis, Chemistry, Integrin, Cell Biology, General Medicine, Hypoxia (medical), Cell biology, Collagen receptor, body regions, Extracellular matrix, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, biology.protein, medicine, medicine.symptom, Transcription factor
Abstract

Tissue hypoxia affects gene expression through the hypoxia-inducible transcription factors, HIF-1 and HIF-2, in both physiological and pathological angiogenesis. Angiogenesis is a complex response of endothelial cells integrating cell proliferation, migration, tube formation, and their interaction with the extracellular matrix through integrin receptors. In this report, we studied the effect of hypoxia on the angiogenic functions of human microvascular endothelial cells (HMEC-1) as well as on expression of the angiogenic integrins αν β3 , αν β5 , and α5 β1 . Exposure of HMEC-1 to hypoxia (1% O2 ) or to DMOG, a prolyl-4-hydroxylase inhibitor, caused significant reduction to their proliferation rate, whereas their migration ability toward laminin-1 or collagen IV and capillary-like tube formation were significantly enhanced. In addition, αv , β1 , β3 , and β5 integrins expression was increased under hypoxia in HMEC-1, while α5 integrin was not affected. Both HIF-1 and HIF-2 protein expression and transcriptional activity were induced under hypoxia in HMEC-1. The knockdown of either HIF-1α or HIF-2α inhibited integrin β3 hypoxic stimulation, suggesting a HIF-dependent induction of β3 integrin in HMEC-1. Taken together, our results indicate that hypoxia transcriptionally up-regulates angiogenic integrins in microvascular endothelial cells along with promoting migration and tube formation of HMEC-1.

Published
2017
Full Text
View/download PDF

33. Neutrophil Gelatinase-Associated Lipocalin as an Early Marker of Contrast-Induced Nephropathy After Elective Invasive Cardiac Procedures

Author

Nikolaos Kafkas, Charalampos I. Liakos, Ourania Dagadaki, Filitsa Zoubouloglou, Konstantinos Makris, and Stylianos Dragasis

Subjects
medicine.medical_specialty, Urinalysis, 030232 urology & nephrology, Urology, Contrast-induced nephropathy, Renal function, 030204 cardiovascular system & hematology, urologic and male genital diseases, Nephropathy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, Creatinine, biology, medicine.diagnostic_test, business.industry, Acute kidney injury, General Medicine, medicine.disease, female genital diseases and pregnancy complications, Surgery, Cystatin C, chemistry, biology.protein, Albuminuria, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

Background Contrast-induced nephropathy (CIN) is an acute kidney injury (AKI) defined as serum creatinine (sCr) increase 48 to 72 hours after contrast administration. Because most subjects undergoing invasive cardiac procedures are discharged within 24 hours, sCr is unsuitable for CIN detection. Hypothesis In the present study we tested the hypothesis that neutrophil gelatinase-associated lipocalin (NGAL) is superior compared with sCr and other established nephropathy markers in early CIN diagnosis after elective invasive cardiac procedures. Methods Serum creatinine, urine creatinine, serum cystatin C, urine albumin, urine NGAL (uNGAL), and plasma NGAL were measured at 0, 6, 24, and 48 hours after contrast administration in 100 elective invasive cardiac procedures. Estimated glomerular filtration rate and albumin-to-creatinine ratio were calculated. Changes from baseline were considered statistically significant at P the biomarker's reference change value. Participants were divided into those with and without clinically significant uNGAL changes (uNGAL positive and negative for AKI, respectively). Results Thirty-three individuals were uNGAL positive for AKI. Serum cystatin C changes were statistically and clinically nonsignificant in both groups. Serum creatinine and plasma NGAL were statistically but not clinically elevated 48 hours postcatheterization in the AKI group. Except for contrast volume (higher in AKI group), groups were comparable at baseline (P not significant) regarding cardiovascular risk factors, coronary heart disease, coronary interventions performed, and renal biomarkers. Baseline uNGAL was significantly correlated to estimated glomerular filtration rate and albumin-to-creatinine ratio. Conclusions Urine NGAL is potentially superior compared with conventional nephropathy markers in early CIN diagnosis after elective invasive cardiac procedures. Definition of clinically significant uNGAL changes with reference change value is probably a valuable supplement to statistically defined significant variations.

Published
2016
Full Text
View/download PDF

35. Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis

Author

Cheng, Matthew P., primary, Orejas, José L., additional, Arbona‐Haddad, Esther, additional, Bold, Tyler D., additional, Solomon, Isaac H., additional, Chen, Kaiwen, additional, Pandit, Alisha, additional, Kusztos, Amanda E., additional, Cummins, Kaelyn C., additional, Liakos, Alexis, additional, Marty, Francisco M., additional, Koo, Sophia, additional, and Hammond, Sarah P., additional

Published
2019
Full Text
View/download PDF

37. Twenty-Four-Hour Urine α1 -Microglobulin as a Marker of Hypertension-Induced Renal Impairment and Its Response on Different Blood Pressure-Lowering Drugs

Author

Nikolaos Kafkas, Dimitrios Tousoulis, Maria I. Markou, Charalampos I. Liakos, Gregory P. Vyssoulis, and Konstantinos Toutouzas

Subjects
Adult, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Tetrazoles, Renal function, Hypertension and the Kidneys, Urine, 030204 cardiovascular system & hematology, Excretion, Diltiazem, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Irbesartan, Internal medicine, Alpha-Globulins, Internal Medicine, Humans, Medicine, 030212 general & internal medicine, Antihypertensive Agents, Creatinine, business.industry, Beta-2 microglobulin, Biphenyl Compounds, Albumin, Middle Aged, Biphenyl compound, Treatment Outcome, Endocrinology, chemistry, Hypertension, Female, Kidney Diseases, Cardiology and Cardiovascular Medicine, business, Biomarkers, Glomerular Filtration Rate, medicine.drug
Abstract

The purpose of this study was to assess the role of urine α(1)‐microglobulin as a marker of hypertension‐induced renal damage compared with estimated glomerular filtration rate, (eGFR), urine albumin, and urine albumin‐to‐creatinine ratio (ACR). Its response on different blood pressure (BP)–lowering drugs was also studied. Sixty never‐treated hypertensive patients (65.0% men, 46.9 years, BP 141.4/94.0 mm Hg) were randomized to an irbesartan (an angiotensin receptor blocker [ARB]) or a diltiazem (a nondihydropyridine calcium channel blocker [CCB])‐based regimen. Patients with diabetes or established cardiovascular, renal, or liver disease were excluded. Blood samples and 24‐hour urine were analyzed at baseline and 6 months after pharmaceutical BP normalization. Serum creatinine was measured and eGFR was calculated. Urine albumin, creatinine, and α(1)‐microglobulin were measured and ACR was calculated. Minor changes (P=not significant [NS]) in eGFR were noted during follow‐up in both groups (from 111.0 mL/min/1.73 m(2) to 108.4 mL/min/1.73 m(2) in the ARB group and from 111.3 mL/min/1.73 m(2) to 114.0 mL/min/1.73 m(2) in the CCB group). Twenty‐four–hour urine indices were all significantly improved (P

Published
2016
Full Text
View/download PDF

38. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Author

Aris Liakos, Apostolos Tsapas, Despoina Vasilakou, Thomas Karagiannis, David R. Matthews, Paschalis Paschos, Maria Rika, Maria Mainou, Panagiota Boura, Eleni Athanasiadou, and Eleni Bekiari

Subjects
Adult, Male, medicine.medical_specialty, Recombinant Fusion Proteins, Endocrinology, Diabetes and Metabolism, Glucagon-Like Peptides, Pharmacology, Cochrane Library, Placebo, Incretins, Drug Administration Schedule, law.invention, Endocrinology, Randomized controlled trial, Glucagon-Like Peptide 1, law, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Glycated Hemoglobin, Venoms, Insulin glargine, business.industry, Metformin, Immunoglobulin Fc Fragments, Albiglutide, Diabetes Mellitus, Type 2, Sitagliptin, Exenatide, Drug Therapy, Combination, Female, Dulaglutide, Peptides, business, medicine.drug
Abstract

Aim To assess the efficacy and safety of recently approved once-weekly glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes. Methods We conducted a systematic review and meta-analysis of randomized controlled trials comparing any GLP-1 RA licensed for once-weekly dosing (albiglutide, dulaglutide or exenatide extended release) with placebo or other antidiabetic agents. We searched Medline, Embase, the Cochrane Library and grey literature for articles published up to December 2014 and extracted data in duplicate. Results In our systematic review we included 33 trials with a total of 16 003 participants. Compared with placebo the change in glycated haemoglobin (HbA1c) concentration was −0.66% [six studies; 95% confidence interval (CI) −1.14 to −0.19; I2 = 88%] with albiglutide, and −1.18% (seven studies; 95% CI −1.34 to −1.02; I2 = 65%) with dulaglutide. Based on data from placebo-controlled trials, we did not detect statistically significant weight-sparing benefits for albiglutide or dulaglutide. Compared with other antidiabetic agents, once-weekly GLP-1 RAs outperformed sitagliptin, daily exenatide and insulin glargine in terms of HbA1c-lowering (mean differences −0.40%; 95% CI −0.66 to −0.14; I2 = 85%, −0.44%; 95% CI −0.58 to −0.29; I2 = 40% and −0.28; 95% CI −0.45 to −0.10; I2 = 81%, respectively). The main adverse effects of treatment included gastrointestinal and injection site reactions. Conclusions Given their dosing scheme and overall efficacy and safety profile, once-weekly GLP-1 RAs are a convenient therapeutic option for use as add-on to metformin.

Published
2015
Full Text
View/download PDF

39. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial

Author

Liakos, Aris, primary, Lambadiari, Vaia, additional, Bargiota, Alexandra, additional, Kitsios, Konstantinos, additional, Avramidis, Iakovos, additional, Kotsa, Kalliopi, additional, Gerou, Spyridon, additional, Boura, Panagiota, additional, Tentolouris, Nikolaos, additional, Dimitriadis, George, additional, and Tsapas, Apostolos, additional

Published
2018
Full Text
View/download PDF

43. PC12 neuron-like cell response to electrospun poly( 3-hydroxybutyrate) substrates

Author

Genchi, Giada Graziana, Ciofani, Gianni, Polini, Alessandro, Liakos, Ioannis, Iandolo, Donata, Athanassiou, Athanassia, Mattoli, Virgilio, Menciassi, Arianna, PISIGNANO, Dario, Genchi, Giada Graziana, Ciofani, Gianni, Polini, Alessandro, Liakos, Ioanni, Iandolo, Donata, Athanassiou, Athanassia, Pisignano, Dario, Mattoli, Virgilio, and Menciassi, Arianna

Subjects
neurite outgrowth, Cell Survival, Surface Properties, Surface Propertie, Dopamine, Polyesters, Polyester, Adrenal Gland Neoplasms, Cell Culture Techniques, Hydroxybutyrates, Neurite, poly(3-hydroxybutyrate), Pheochromocytoma, PC12 Cells, Hydroxybutyrate, Nerve Growth Factor, Cell Adhesion, Neurites, Animals, electrospinning, PC12 cell, Cell Proliferation, Neurons, Animal, Photoelectron Spectroscopy, sub-micron fibres, Cell Differentiation, Neuron, sub-micron fibre, PC12 cells, dopamine, Adsorption, Collagen, Rats, Adrenal Gland Neoplasm, Rat
Abstract

In the last decade, the importance of topographic properties of extracellular environments has been shown to be essential to addressing cell response, especially when replacing damaged tissues with functional constructs obtained in vitro. In the current study, densely packed sub-micron poly(3-hydroxybutyrate) (PHB) fibres were electrospun with random and parallel orientations. PC12 pheochromocytoma cells that mimic central dopaminergic neurons and represent a model for neuronal differentiation were cultured on collagen-coated fibres to evaluate cell response dependence on substrate topography. Cell adhesion, viability and proliferation, as well as dopamine production were evaluated after three days since seeding. Cell differentiation was examined in terms of neurite number, orientation and length 6 days after administration of nerve growth factor (NGF). Results showed that proliferating PC12 cells secreted a higher quantity of dopamine on fibres with respect to control cultures and as a result, a possible use of PHB fibres was considered for cell transplantation in the central nervous system when local production of dopamine is impaired. Differentiated PC12 cells were characterized by highly aligned and longer neurites on parallel PHB fibres with respect to random fibres, thereby demonstrating the suitability of parallel PHB fibres for further studies in peripheral nervous system regeneration.

Published
2015

44. The Interplay of Exercise Heart Rate and Blood Pressure as a Predictor of Coronary Artery Disease and Arterial Hypertension

Author

Christodoulos Stefanadis, Andreas P. Michaelides, Evangelos I. Chatzistamatiou, Charalampos I. Liakos, Maria I. Markou, Gregory P. Vyssoulis, and Vanessa Tzamou

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Endocrinology, Diabetes and Metabolism, Confounding, medicine.disease, Confidence interval, Surgery, Coronary artery disease, Blood pressure, Relative risk, Internal medicine, Heart rate, Internal Medicine, medicine, Cardiology, Exercise physiology, Cardiology and Cardiovascular Medicine, business, Electrocardiography
Abstract

Delayed blood pressure (BP) and heart rate (HR) decline at recovery post-exercise are independent predictors of incident coronary artery disease (CAD). Delayed BP recovery and exaggerated BP response to exercise are independent predictors of future arterial hypertension (AH). This study sought to examine whether the combination of two exercise parameters provides additional prognostic value than each variable alone. A total of 830 non-CAD patients (374 normotensive) were followed for new-onset CAD and/or AH for 5 years after diagnostic exercise testing (ET). At the end of follow-up, patients without overt CAD underwent a second ET. Stress imaging modalities and coronary angiography, where appropriate, ruled out CAD. New-onset CAD was detected in 110 participants (13.3%) whereas AH was detected in 41 former normotensives (11.0%). The adjusted (for confounders) relative risk (RR) of CAD in abnormal BP and HR recovery patients was 1.95 (95% confidence interval [CI], 1.28-2.98; P=.011) compared with delayed BP and normal HR recovery patients and 1.71 (95% CI, 1.08-2.75; P=.014) compared with normal BP and delayed HR recovery patients. The adjusted RR of AH in normotensives with abnormal BP recovery and response was 2.18 (95% CI, 1.03-4.72; P=.047) compared with delayed BP recovery and normal BP response patients and 2.48 (95% CI, 1.14-4.97; P=.038) compared with normal BP recovery and exaggerated BP response individuals. In conclusion, the combination of two independent exercise predictors is an even stronger CAD/AH predictor than its components.

Published
2012
Full Text
View/download PDF

45. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

Author

Christina Befani, Christos N. Papandreou, Panagiotis Liakos, Ioannis A. Voutsadakis, Panagiotis J. Vlachostergios, Eleana Hatzidaki, Danai D. Daliani, Konstantinos Tsapakidis, Anna Patrikidou, and George Moutzouris

Subjects
Cell growth, Bortezomib, Urology, Biology, medicine.disease, Vascular endothelial growth factor, chemistry.chemical_compound, Prostate cancer, Proteasome, chemistry, LNCaP, Proteasome inhibitor, medicine, Cancer research, Protein kinase A, medicine.drug
Abstract

Objectives: Neuropeptides are important signal initiators in advanced prostate cancer, partially acting through activation of nuclear factor kappa B. Central to nuclear factor kappa B regulation is the ubiquitin-proteasome system, pharmacological inhibition of which has been proposed as an anticancer strategy. We investigated the putative role of the proteasome inhibitor bortezomib in neuropeptides signaling effects on prostate cancer cells. Methods: Human prostate cancer cell lines, LNCaP and PC-3, were used to examine cell proliferation, levels of proapoptotic (caspase-3, Bad) and cell cycle regulatory proteins (p53, p27, p21), as well as total and phosphorylated Akt and p44/42 mitogen-activated protein kinase proteins. Furthermore, 20S proteasome activity, subcellular localization of nuclear factor kappa B and transcription of nuclear factor kappa B target genes, interleukin-8 and vascular endothelial growth factor, were assessed. Results: Neuropeptides (endothelin-1, bombesin) increased cell proliferation, whereas bortezomib decreased proliferation and induced apoptosis, an effect maintained after cotreatment with neuropeptides. Bad, p53, p21 and p27 were downregulated by neuropeptides in PC-3, and these effects were reversed with the addition of bortezomib. Neuropeptides increased proteasomal activity and nuclear factor kappa B levels in PC-3, and these effects were prevented by bortezomib. Interleukin-8 and vascular endothelial growth factor transcripts were induced after neuropeptides treatment, but downregulated by bortezomib. These results coincided with the ability of bortezomib to reduce mitogen-activated protein kinase signaling in both cell lines. Conclusions: These findings are consistent with bortezomib-mediated abrogation of neuropeptides-induced proliferative and antiapoptotic signaling. Thus, the effect of the drug on the neuropeptides axis needs to be further investigated, as neuropeptide action in prostate cancer might entail involvement of the proteasome.

Published
2012
Full Text
View/download PDF

46. Electricity-renewables & transmission: Hidden challenges and increasing rewards of renewable procurement

Author

Harold T. Judd and Kathleen Liakos

Subjects
Commerce, Renewable energy credit, Procurement, Hydroelectricity, business.industry, Process (engineering), Economics, Electricity, Environmental economics, Feed-in tariff, business, Renewable energy, Renewable resource
Abstract

The increasing prevalence of renewable energy development brings several issues to light within the energy procurement industry. Consumers and utility companies alike are taking advantage of the benefits of the cleaner renewable energy sources such as solar, wind, biomass, geothermal, methane capture, and low-head hydroelectric. However, the benefits of renewable resources are at times offset by costs that are unknown to the public, and at times to developers. In particular, too often little thought is given to the cost of transmission and distribution systems needed to deliver electricity from a project to the ultimate customer. Also, the process for procuring electricity from renewable projects is often misunderstood. What follows is a brief introduction to the typical procurement process and the challenges facing developers and the utilities that buy their output.

Published
2012
Full Text
View/download PDF

47. Correlation of urinary excretion of sodium with severity of sleep-disordered breathing in children: A preliminary study

Author

Evangelos Boultadakis, Emmanouel I. Alexopoulos, Eleni Kostadima, Konstantinos I. Gourgoulianis, Nikolaos Liakos, Konstantinos Evangelopoulos, Vasiliki Varlami, Epameinondas Zakynthinos, Elias Zintzaras, and Athanasios G. Kaditis

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Fractional excretion of sodium, Ambulatory blood pressure, medicine.diagnostic_test, business.industry, Sleep apnea, Polysomnography, medicine.disease, respiratory tract diseases, Natriuresis, Excretion, Obstructive sleep apnea, Internal medicine, Anesthesia, Pediatrics, Perinatology and Child Health, medicine, Cardiology, business, Morning
Abstract

Background Nocturnal urinary sodium excretion is related to blood pressure (BP) levels. Elevated BP and increased nocturnal natriuresis have been demonstrated in adults with sleep apnea. Although evidence indicates increased BP in children with obstructive sleep-disordered breathing (SDB), it is unknown whether these children have also enhanced urinary sodium excretion. Objective To evaluate the effects of SDB and morning BP on urinary sodium excretion. Methods Consecutive children with snoring (n = 95) underwent polysomnography and morning BP measurement. Fractional excretion of sodium (FENa) was the primary outcome measure and was calculated using sodium and creatinine concentrations in early morning serum and urine specimens. Results Subjects with moderate-to-severe SDB had similar log-transformed FENa to that of children with mild SDB and higher than children with primary snoring: −0.13 ± 0.53 versus −0.28 ± 0.41 versus −0.61 ± 0.65 (P = 0.657 and P = 0.003). Obstructive apnea–hypopnea index was significantly related to FENa after adjustment for age, gender and body mass index z-score (P = 0.002). Children with moderate-to-severe SDB had similar systolic BP z-scores to those of subjects with mild SDB and higher than participants with primary snoring: 0.7 ± 1.2 versus 0.1 ± 1.0 versus −0.02 ± 1.0 (P = 0.074 and P = 0.046). In addition, participants with diastolic BP z-scores in the upper quartile of measured values had higher FENa than subjects with z-scores in the lower quartiles: −0.08 ± 0.39 versus −0.41 ± 0.57 (P = 0.007). Conclusions Morning natriuresis is related to severity of SDB in children and this association may be mediated in part by elevated BP. Pediatr Pulmonol. 2010; 45:999–1004. © 2010 Wiley-Liss, Inc.

Published
2010
Full Text
View/download PDF

48. Weak imposition of boundary conditions for the Navier-Stokes equations by a penalty method

Author

Anastasios Liakos and Atife Caglar

Subjects
Mathematical optimization, Applied Mathematics, Mechanical Engineering, Computational Mechanics, Boundary (topology), Mixed boundary condition, Boundary knot method, Singular boundary method, Robin boundary condition, Computer Science Applications, Physics::Fluid Dynamics, Mechanics of Materials, Applied mathematics, Penalty method, Boundary value problem, Navier–Stokes equations, Mathematics
Abstract

We prove convergence of the finite element method for the Navier―Stokes equations in which the no-slip condition and no-penetration condition on the flow boundary are imposed via a penalty method. This approach has been previously studied for the Stokes problem by Liakos (Weak imposition of boundary conditions in the Stokes problem. Ph.D. Thesis, University of Pittsburgh, 1999). Since, in most realistic applications, inertial effects dominate, it is crucial to extend the validity of the method to the nonlinear Navier―Stokes case. This report includes the analysis of this extension, as well as numerical results validating their analytical counterparts. Specifically, we show that optimal order of convergence can be achieved if the computational boundary follows the real flow boundary exactly.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results